A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 28 Days in Atherogenic Dyslipidaemic Patients With Abdominal Obesity. A Double Blind, Placebo-controlled and Randomized Study.

Trial Profile

A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 28 Days in Atherogenic Dyslipidaemic Patients With Abdominal Obesity. A Double Blind, Placebo-controlled and Randomized Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 May 2013

At a glance

  • Drugs Elafibranor (Primary)
  • Indications Dyslipidaemias; Fatty liver; Metabolic syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2013 A combined analysis of four phase IIa studies was published in Hepatology, according to a GENFIT media release.
    • 24 Sep 2010 Results were presented as part of a series of results at the 46th Annual Meeting of the European Association for the Study of Diabetes.
    • 29 Jun 2010 Results presented at ADA 2010, according to a Genfit media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top